Literature DB >> 10211112

The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region.

P D Sturm1, R H Hruban, T B Ramsoekh, L A Noorduyn, G N Tytgat, D J Gouma, G J Offerhaus.   

Abstract

It can be difficult to distinguish between malignant and benign disease of the region of the head of the pancreas using conventional methods. K-ras and p53 alterations occur frequently in malignancies in this region and are therefore candidate tumour markers. To define the utility of these alterations in interpreting pancreatic head cytology, the present study investigated to what extent alterations in the carcinomas were detectable on cytology and whether the alterations found in the cytology came from the carcinomas. Fifty-seven consecutive pancreaticoduodenectomy resection specimens (52 with a malignancy and five without) and the ductal brush cytology specimens collected post-operatively from these resection specimens were compared for the presence of K-ras and p53 alterations. K-ras mutations were detected using the polymerase chain reaction (PCR) and allele-specific oligonucleotide hybridization, and p53 alterations using immunochemical staining for the p53 gene product. After discrepancy analysis, the results from the resection specimens and corresponding brush cytology specimens were identical in 88 per cent for the K-ras analysis and in 84 per cent for the p53 analysis. In two cases, K-ras mutations found in the brush cytology specimens were not derived from the carcinoma but from pancreatic ductal hyperplasias. Intratumour heterogeneity and sampling error were also identified as causes for discrepant results. The five resection specimens without a malignancy and the corresponding brush cytology specimens were negative for both genetic alterations. In conclusion, the detection of K-ras and p53 alterations in cells obtained from the pancreatic head region might be a valuable adjunct to conventional cytology for the diagnosis of malignancies in the pancreatic head region. However, intratumour heterogeneity, mucinous pancreatic duct hyperplasia harbouring K-ras mutations, and sampling error will hinder their diagnostic accuracy in routine clinical use.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10211112     DOI: 10.1002/(SICI)1096-9896(1998110)186:3<247::AID-PATH179>3.0.CO;2-J

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  15 in total

Review 1.  Molecular diagnosis of pancreatobiliary malignancies in brush cytologies of biliary strictures.

Authors:  T M Gress
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

Review 2.  Focal intrahepatic strictures: a review of diagnosis and management.

Authors:  David Yeo; Marcos Vinicius Perini; Vijayaragavan Muralidharan; Christopher Christophi
Journal:  HPB (Oxford)       Date:  2012-07       Impact factor: 3.647

Review 3.  Identifying molecular markers for the early detection of pancreatic neoplasia.

Authors:  Michael Goggins
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

4.  Management of hepatobiliary and pancreatic disorders at the Academic Medical Center Amsterdam, Netherlands.

Authors:  D J Gouma; H Obertop
Journal:  HPB (Oxford)       Date:  2002       Impact factor: 3.647

Review 5.  Molecular markers of pancreatic cancer: development and clinical relevance.

Authors:  Lucia C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Langenbecks Arch Surg       Date:  2008-02-12       Impact factor: 3.445

6.  Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology.

Authors:  Lester J Layfield; Hormoz Ehya; Armando C Filie; Ralph H Hruban; Nirag Jhala; Loren Joseph; Philippe Vielh; Martha B Pitman
Journal:  Diagn Cytopathol       Date:  2014-04       Impact factor: 1.582

Review 7.  Pancreatic cancer screening.

Authors:  Eun Ji Shin; Marcia Irene Canto
Journal:  Gastroenterol Clin North Am       Date:  2012-01-05       Impact factor: 3.806

8.  Pancreatic cancer after remote peptic ulcer surgery.

Authors:  M Tascilar; B P van Rees; P D J Sturm; G N J Tytgat; R H Hruban; S N Goodman; F M Giardiello; G J A Offerhaus; A C Tersmette
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

9.  Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer.

Authors:  Min Li; Uddalak Bharadwaj; Rongxin Zhang; Sheng Zhang; Hong Mu; William E Fisher; F Charles Brunicardi; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer Ther       Date:  2008-02       Impact factor: 6.261

10.  The role of preoperative biopsy in pancreatic cancer.

Authors:  D L Clarke; B A Clarke; S R Thomson; O J Garden; N G Lazarus
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.